Company: HCTI
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026218
Chunk: 35

Company: Healthcare Triangle, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 35
---
 additional compliance period at that time, the Nasdaq Listing Qualifications
Department staff will provide us written notification that our common stock may be delisted. At that time, we may appeal the staff’s
delisting determination to a Nasdaq Listing Qualifications Panel. We expect that our common stock would remain listed pending the panel’s
decision. However, there can be no assurance that, even if we appeal the staff’s delisting determination to the Nasdaq Listing Qualifications
Panel, such appeal would be successful.

There are many factors that may adversely affect
our minimum bid price, including those described throughout this section titled “Risk Factors.” Many of these factors are
outside of our control. As a result, we may not be able to sustain compliance with the minimum bid price rule in the long term. Any potential
delisting of our common stock from the Nasdaq Capital Market would likely result in decreased liquidity and increased volatility for our
common stock and would adversely affect our ability to raise additional capital or to enter into strategic transactions. Any potential
delisting of our common stock from the Nasdaq Capital Market would also make it more difficult for our stockholders to sell our common
stock in the public market.

The Company and its products are subject to
laws and regulations concerning electronic prescribing standards and the adoption of controlled substance electronic prescribing. Our
actual or perceived failure to comply with these laws and regulations could harm our business, financial condition, results of operations,
reputation, or prospects.

The use of our software by physicians to perform
a variety of functions, including electronic prescribing, which refers to the electronic routing of prescriptions to pharmacies and the
ensuing dispensation, is governed by state and federal law, including fraud and abuse laws. States have differing prescription format
requirements, which we have programmed into our software. There is significant variation in the laws and regulations governing prescription
activity, as federal law and the laws of many states permit the electronic transmission of certain controlled prescription orders, while
the laws of several states neither specifically permit nor specifically prohibit the practice. Restrictions exist at the federal level
on the use of electronic prescribing for controlled substances and certain other drugs, including a regulation enacted by the Drug Enforcement
Association in mid-2010. However, some states (most notably New York) have passed complementary laws governing the use of electronic prescribing
tools in the use of prescribing opioids and other controlled substances, and we expect this to continue to be addressed with regulations
in other states. In addition, the HHS published its final